Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
Holding IOBT?
Track your performance easily
IOBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $2.10
Previous Close$1.16
Volume618.93K
Average Volume (3M)423.46K
Market Cap
$76.42M
Enterprise Value-$22.18M
Total Cash (Recent Filing)$100.75M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding65,880,914
10 Day Avg. Volume1,652,618
30 Day Avg. Volume423,458
Standard Deviation0.23
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$9.00Price Target Upside656.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
IO Biotech News
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalPositive topline results would be sufficient to support full approval of IO102-IO103 in 1L melanoma.
Safety ProfileThe safety profile was manageable with low rates of Grade 3/4 adverse events.
Study ResultsResponses were seen in both HPV+ and HPV- patients, demonstrating potential for broad efficacy.
Bears Say
Analysis OutcomeThe most likely scenario is the interim ORR analysis misses and the study continues to final PFS data.
Clinical TrialsPh3 study of IO102-IO103 + pembro in advanced melanoma did not meet the very high bar for success on the interim ORR analysis.
Statistical ChallengesThe chances of the interim analysis hitting are low given the high statistical bar, leaving a positive outcome as upside.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.73 and its highest was $2.10 in the past 12 months.
What is IO Biotech’s market cap?
Currently, no data Available
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Mar 27, 2025 which is in 188 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Aug 13, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.03.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 17.692%.
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at N/A.
---
IO Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (656.30% Upside)
$9.00 (656.30% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $98.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 27.5%
Last 30 Days ▲ 27.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.54%
12-Months-Change
Fundamentals
Return on Equity
-87.66%
Trailing 12-Months
Asset Growth
-5.18%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
---
IOBT Stock 12 Month Forecast
Average Price Target
$9.00
▲(656.30% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kala Pharmaceuticals
―
Oncternal Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-18.78%
reiterated a buy rating 4 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -18.78% per trade.
---